MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13696998.2026.2738356

Медицинская библиотека · Journal of medical economics · 2026

Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort study.

Ralphs Eleanor, Prabhu Vimalanand S, Landfeldt Erik, Ridsdale-Smith Jess, Teoh Cheryl, Macey Karen, Trankov Nikolay, Lambova Alexandrina, Lichfield Jasmine, Eminowicz Gemma

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To describe real-world treatment patterns, healthcare resource utilization (HCRU), and hospital-based non-drug direct medical costs of patients with high-risk endometrial cancer (HR-EC) from initiation of first adjuvant therapy in England.

METHODS

Adult women with HR-EC (i.e. stage I/II EC with non-endometrioid histology or stage III/IVa EC with any histology) who received adjuvant therapy within 90 days after surgery were identified via England's National Cancer Registration and Analysis Service. Treatment patterns, annual rates of HCRU, and non-drug direct medical costs (in 2022 £) were described from the first adjuvant therapy.

RESULTS

In total, 6,036 women (mean age: 67 years, 86% White) were included. The most commonly prescribed adjuvant therapy was radiation therapy (43%), followed by chemoradiotherapy (37%), and systemic chemotherapy (19%). Across the first four lines of therapy, there were 80 unique treatment sequences. The majority of patients (79%) did not receive further treatment after the adjuvant therapy. Amongst those that did, the most common treatment across all subsequent lines was systemic chemotherapy. In the total cohort, the mean annual rate of inpatient, outpatient, and A&E visits was 2.8, 12.5, and 1.0, respectively, corresponding to a mean non-drug direct medical cost per year of £4,581. Patients who experienced recurrence exhibited higher HCRU and costs over follow-up, reflecting overall healthcare utilization trajectories among patients who ultimately recurred rather than costs directly attributable to recurrence.

CONCLUSIONS

Our study provides novel insights into the real-world treatment patterns, HCRU, and non-drug direct medical costs associated with HR-EC in England. The substantial clinical and economic burden underscores the need for ongoing research and optimization of treatment strategies.

Для цитирования: Ralphs Eleanor, Prabhu Vimalanand S, Landfeldt Erik, Ridsdale-Smith Jess, Teoh Cheryl, Macey Karen, Trankov Nikolay, Lambova Alexandrina, Lichfield Jasmine, Eminowicz Gemma. Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort study.. Journal of medical economics. 2026. DOI: 10.1080/13696998.2026.2738356.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.